Mirati Therapeutics Inc. (MRTX)
NASDAQ: MRTX
· Real-Time Price · USD
58.70
-0.10 (-0.17%)
At close: Jan 22, 2024, 9:00 PM
-0.17% (1D)
| Bid | n/a |
| Market Cap | 4.12B |
| Revenue (ttm) | 38.19M |
| Net Income (ttm) | -716.64M |
| EPS (ttm) | -12.18 |
| PE Ratio (ttm) | -4.819376026272578 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | n/a |
| Volume | 20,956,839 |
| Avg. Volume (20D) | 1,778,618 |
| Open | 58.86 |
| Previous Close | 58.80 |
| Day's Range | 58.54 - 58.99 |
| 52-Week Range | 27.30 - 64.41 |
| Beta | 0.77 |
About MRTX
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase 3 clinical tr...
Industry Biotechnology
Sector Healthcare
IPO Date Jul 15, 2013
Employees 587
Stock Exchange NASDAQ
Ticker Symbol MRTX
Website https://www.mirati.com